Trial · NCT01314716
Adverse events256
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 256
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Cough | Respiratory, thoracic and mediastinal disorders | AZLI-AZLI (Double-Blind) | 66 | 135 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Placebo-AZLI (Double-Blind) | 65 | 137 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | AZLI-AZLI (Open-Label) | 27 | 112 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Placebo-AZLI (Open-Label) | 38 | 110 | |
| other | Sputum increased | Respiratory, thoracic and mediastinal disorders | AZLI-AZLI (Double-Blind) | 59 | 135 | |
| other | Sputum increased | Respiratory, thoracic and mediastinal disorders | Placebo-AZLI (Double-Blind) | 50 | 137 | |
| other | Sputum increased | Respiratory, thoracic and mediastinal disorders | AZLI-AZLI (Open-Label) | 19 | 112 | |
| other | Sputum increased | Respiratory, thoracic and mediastinal disorders | Placebo-AZLI (Open-Label) | 23 | 110 | |
| other | Sputum discoloured | Respiratory, thoracic and mediastinal disorders | AZLI-AZLI (Double-Blind) | 48 | 135 | |
| other | Sputum discoloured | Respiratory, thoracic and mediastinal disorders | Placebo-AZLI (Double-Blind) | 38 | 137 | |
| other | Sputum discoloured | Respiratory, thoracic and mediastinal disorders | AZLI-AZLI (Open-Label) | 21 | 112 | |
| other | Sputum discoloured | Respiratory, thoracic and mediastinal disorders | Placebo-AZLI (Open-Label) | 18 | 110 | |
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | AZLI-AZLI (Double-Blind) | 50 | 135 | |
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | Placebo-AZLI (Double-Blind) | 47 | 137 | |
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | AZLI-AZLI (Open-Label) | 26 | 112 | |
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | Placebo-AZLI (Open-Label) | 28 | 110 | |
| other | Wheezing | Respiratory, thoracic and mediastinal disorders | AZLI-AZLI (Double-Blind) | 18 | 135 | |
| other | Wheezing | Respiratory, thoracic and mediastinal disorders | Placebo-AZLI (Double-Blind) | 13 | 137 | |
| other | Wheezing | Respiratory, thoracic and mediastinal disorders | AZLI-AZLI (Open-Label) | 11 | 112 | |
| other | Wheezing | Respiratory, thoracic and mediastinal disorders | Placebo-AZLI (Open-Label) | 7 | 110 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01314716/events